OncoResponse lands $27M to advance development of antibody-based treatments for cancer — Seattle biotech company OncoResponse landed $27 million to advance the development and testing of its antibody-based immunotherapy treatments that… Read More
OncoResponse raises $40M to start clinical trials of antibody-based cancer immunotherapies OncoResponse, a Seattle biotech company creating antibody-based treatments for cancer, has raised a $40 million Series B round to advance… Read More
